Brain.Q Technologies Inc.

BrainQ operates in the medical-device and digital-neurology segment, developing non-invasive neurorehabilitation technology with an initial focus on recovery after ischemic stroke. Its approach combines a wearable device that delivers low-intensity, low-frequency electromagnetic stimulation with AI-supported personalization and a clinician-guided home rehabilitation service. This gives the company a distinct product emphasis on delivering therapy outside conventional clinic settings, while pairing stimulation with exercises and remote monitoring. The company announced CE Mark achievement for its stroke therapy in January 2025 and launched a home-based service in Israel in February 2026, providing evidence of regulatory and commercialization milestones. Its stated categories place it alongside health-care, medical, and medical-device businesses, but the available company information does not identify reliable named competitors; comparisons with specific companies would therefore be speculative. Nor is there enough information to quantify adoption, clinical outcomes, market share, or comparative efficacy. BrainQ’s competitive position is best understood as that of a specialized neurotechnology developer translating electromagnetic stimulation and AI-guided care into a home-based stroke recovery program, rather than as a broadly diversified medical-device company.

BrainQ was founded in 2016 and has disclosed two funding rounds: an $8.8 million Series A on May 15, 2018, followed by a $40 million Series B on August 16, 2021, led by Hanaco Venture Capital. The $40 million round is the latest disclosed financing, so the available funding history indicates substantial earlier investment but does not establish the company’s current capital position. A key development milestone came in January 2025, when BrainQ announced CE Mark achievement for its stroke therapy and Stacey Pugh’s appointment as board chair. On February 25, 2026, it announced a home-based AI brain recovery service in Israel and appointed Professor Jeffrey L. Saver as medical director to support launch and clinical development. Together, those steps suggest a shift from therapy development and regulatory progress toward service delivery and clinical implementation. Information on the service’s uptake, revenue, additional markets, and post-2021 financing is limited, so the scale and pace of commercialization remain uncertain.